Adagene of Suzhou was approved to begin US trials of its lead product, ADG-106, in patients with advanced solid tumors and non-Hodgkin lymphoma, the first trial of any Adagene candidate. ADG-106 is a fully human mAb that targets a novel epitope of CD137, a member of the tumor necrosis factor (TNF) receptor superfamily. The company said ADG-106 is the only mAb against this target to show potent single agent efficacy in multiple tumor models. It plans to begin the trial in the second half of the year. More details....
Share this with colleagues:
Original Article: Adagene Approved to Begin US Trials of I-O Cancer Candidate